# Fangliang (Frank) Zhang

Source: https://onco.cc/people/zhang-fangliang/  
OnCo record `zhang-fangliang` (Person). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Frank Zhang founded GenScript and its cell therapy spin-out Legend Biotech, whose Nanjing team invented the myeloma CAR-T that became Carvykti.

## Summary

Zhang founded GenScript in New Jersey in 2002 and moved it to Nanjing; Legend Biotech, spun out in 2014, developed the llama-derived BCMA CAR-T LCAR-B38M (LEGEND-2), partnered it with Janssen in 2017 and listed on Nasdaq in 2020; ciltacabtagene autoleucel was approved by the FDA in 2022 and the NMPA in 2024. He stepped back from executive roles in 2021.

## Fields

- Kind: Person
- Last checked: 2026-09-10
- Also known as: Frank Zhang; 张方亮
- Tags: china
- Role: Founder and former Chairman, Legend Biotech; former Chairman, GenScript Biotech
- Specialisms: Cell therapy; Biotech leadership; Gene synthesis

## Sources

- Legend Biotech: https://www.legendbiotech.com/

## Connected records

- drugs: [Ciltacabtagene autoleucel](https://onco.cc/drugs/ciltacabtagene-autoleucel/)
- companies: [Legend Biotech](https://onco.cc/companies/legend-biotech/)
- trials: [CARTITUDE-1](https://onco.cc/trials/cartitude-1/), [LEGEND-2](https://onco.cc/trials/legend-2/)

---
JSON: https://onco.cc/api/v1/entities/zhang-fangliang.json